

Generic Name: Pimavanserin**Preferred:** N/A**Therapeutic Class or Brand Name:** Nuplazid®**Non-preferred:** N/A**Applicable Drugs (if Therapeutic Class):****Date of Origin:** 3/23/2020

Second Generation Antipsychotic

Date Last Reviewed / Revised: 11/3/2023

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I - VI are met)

- I. Documented diagnosis of hallucinations and delusions associated with Parkinson's disease psychosis. Clinically significant treatment failure, adverse event, or contraindication to A and B
 - A. One of the following antipsychotics
 1. Quetiapine
 2. Clozapine
 - B. Rivastigmine
- II. Treatment must be prescribed by or in consultation with a geriatrician, psychiatrist or neurologist.
- III. Must be 18 years of age or older.
- IV. Refer to plan document for the list of preferred products. If requested agent is not listed as a preferred product, must have a documented failure, intolerance, or contraindication to the preferred product(s).

EXCLUSION CRITERIA

- Elderly patients (≥ 65 years of age) with a documented history of dementia-related psychosis and concurrent treatment with antipsychotics.
- Documented dementia-related psychosis that are unrelated to hallucinations associated with Parkinson's disease.

OTHER CRITERIA

- N/A

QUANTITY / DAYS SUPPLY RESTRICTIONS

- 10 mg tablets, 34 mg capsules
- 30 tablets/capsules per 30 days.

APPROVAL LENGTH

- **Authorization:** 12 months
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

APPENDIX

N/A

REFERENCES

1. Nuplazid™ [Package Insert], San Diego, CA; Acadia Pharmaceuticals Inc; 2023
<https://www.nuplazid.com/pdf/nuplazid-prescribing-information.pdf>
2. Rogers G, Parkinson's disease: summary of updated NICE guidance. *BMJ*. 2019 Feb 28;364:l961. PMID: 28751362.
3. Powell A, Matar E, Lewis SJG. Treating hallucinations in Parkinson's disease. *Expert Rev Neurother*. 2022;22(6):455-468. doi:10.1080/14737175.2021.1851198
4. Combs BL, Cox AG. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. *Neuropsychiatr Dis Treat*. 2017;13:737-744.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352252/>

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.